EUR 26.78
(2.53%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 37.6 Million EUR | -16.77% |
2022 | 45.17 Million EUR | -2.12% |
2021 | 46.15 Million EUR | 3.23% |
2020 | 44.71 Million EUR | -1.58% |
2019 | 45.42 Million EUR | 1029.49% |
2018 | 4.02 Million EUR | 31.65% |
2017 | 3.05 Million EUR | -23.76% |
2016 | 4 Million EUR | 18.13% |
2015 | 3.39 Million EUR | -53.37% |
2014 | 7.27 Million EUR | -5.26% |
2013 | 7.67 Million EUR | -25.65% |
2012 | 10.32 Million EUR | 23.97% |
2011 | 8.33 Million EUR | -16.56% |
2010 | 9.98 Million EUR | -7.8% |
2009 | 10.82 Million EUR | -4.59% |
2008 | 11.35 Million EUR | 0.0% |
2005 | 5.74 Million EUR | 65.0% |
2004 | 3.48 Million EUR | -35.76% |
2003 | 5.41 Million EUR | -28.76% |
2002 | 7.6 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 35.4 Million EUR | -5.85% |
2024 Q2 | 33.1 Million EUR | -6.5% |
2024 Q3 | 31.5 Million EUR | -4.83% |
2023 Q1 | 47.8 Million EUR | 5.81% |
2023 FY | 37.6 Million EUR | -16.77% |
2023 Q4 | 37.6 Million EUR | 5.92% |
2023 Q3 | 35.5 Million EUR | -1.11% |
2023 Q2 | 35.9 Million EUR | -24.9% |
2022 Q4 | 45.17 Million EUR | 8.59% |
2022 Q1 | 40.2 Million EUR | -12.9% |
2022 Q3 | 41.6 Million EUR | 2.21% |
2022 FY | 45.17 Million EUR | -2.12% |
2022 Q2 | 40.7 Million EUR | 1.24% |
2021 Q2 | 41.5 Million EUR | -1.89% |
2021 FY | 46.15 Million EUR | 3.23% |
2021 Q1 | 42.3 Million EUR | -5.39% |
2021 Q4 | 46.15 Million EUR | 13.4% |
2021 Q3 | 40.7 Million EUR | -1.93% |
2020 FY | 44.71 Million EUR | -1.58% |
2020 Q2 | 44.4 Million EUR | 6.73% |
2020 Q1 | 41.6 Million EUR | -8.43% |
2020 Q4 | 44.71 Million EUR | 3.5% |
2020 Q3 | 43.2 Million EUR | -2.7% |
2019 FY | 45.42 Million EUR | 1029.49% |
2019 Q2 | 48.6 Million EUR | 816.98% |
2019 Q1 | 5.3 Million EUR | 31.78% |
2019 Q3 | 46.3 Million EUR | -4.73% |
2019 Q4 | 45.42 Million EUR | -1.88% |
2018 FY | 4.02 Million EUR | 31.65% |
2018 Q4 | 4.02 Million EUR | 8.7% |
2018 Q1 | 3.8 Million EUR | 24.39% |
2018 Q2 | 3 Million EUR | -21.05% |
2018 Q3 | 3.7 Million EUR | 23.33% |
2017 Q1 | 5.2 Million EUR | 29.77% |
2017 FY | 3.05 Million EUR | -23.76% |
2017 Q3 | 4.3 Million EUR | -4.44% |
2017 Q2 | 4.5 Million EUR | -13.46% |
2017 Q4 | 3.05 Million EUR | -28.95% |
2016 Q3 | 3.5 Million EUR | 16.67% |
2016 Q4 | 4 Million EUR | 14.49% |
2016 Q1 | 3.6 Million EUR | 6.13% |
2016 Q2 | 3 Million EUR | -16.67% |
2016 FY | 4 Million EUR | 18.13% |
2015 Q4 | 3.39 Million EUR | 13.07% |
2015 FY | 3.39 Million EUR | -53.37% |
2015 Q1 | 4.4 Million EUR | -39.52% |
2015 Q2 | 3.1 Million EUR | -29.55% |
2015 Q3 | 3 Million EUR | -3.23% |
2014 Q4 | 7.27 Million EUR | 65.34% |
2014 Q3 | 4.4 Million EUR | -30.16% |
2014 FY | 7.27 Million EUR | -5.26% |
2014 Q1 | 8.9 Million EUR | 15.9% |
2014 Q2 | 6.3 Million EUR | -29.21% |
2013 FY | 7.67 Million EUR | -25.65% |
2013 Q3 | 6.3 Million EUR | -16.0% |
2013 Q2 | 7.5 Million EUR | -23.47% |
2013 Q1 | 9.8 Million EUR | -5.11% |
2013 Q4 | 7.67 Million EUR | 21.89% |
2012 Q1 | 8.6 Million EUR | 3.23% |
2012 FY | 10.32 Million EUR | 23.97% |
2012 Q4 | 10.32 Million EUR | 13.49% |
2012 Q3 | 9.1 Million EUR | -2.15% |
2012 Q2 | 9.3 Million EUR | 8.14% |
2011 Q3 | 7.8 Million EUR | -26.42% |
2011 Q4 | 8.33 Million EUR | 6.81% |
2011 Q2 | 10.6 Million EUR | 2.91% |
2011 Q1 | 10.3 Million EUR | 3.17% |
2011 FY | 8.33 Million EUR | -16.56% |
2010 Q2 | 10.3 Million EUR | -10.43% |
2010 Q4 | 9.98 Million EUR | -4.0% |
2010 FY | 9.98 Million EUR | -7.8% |
2010 Q3 | 10.4 Million EUR | 0.97% |
2010 Q1 | 11.5 Million EUR | 6.2% |
2009 Q4 | 10.82 Million EUR | 0.0% |
2009 FY | 10.82 Million EUR | -4.59% |
2008 FY | 11.35 Million EUR | 0.0% |
2005 FY | 5.74 Million EUR | 65.0% |
2004 FY | 3.48 Million EUR | -35.76% |
2003 FY | 5.41 Million EUR | -28.76% |
2002 FY | 7.6 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
BBS-Bioactive Bone Substitutes Oyj | 5.5 Million EUR | -583.015% |
Modulight Oyj | 8.23 Million EUR | -356.588% |
Nexstim Plc | 7.04 Million EUR | -433.576% |